Lepu Biopharma Co., Ltd. (HKG:2157)

Lepu Biopharma Statistics

Total Valuation

Lepu Biopharma has a market cap or net worth of HKD 13.62 billion. The enterprise value is 14.00 billion.

Market Cap	13.62B
Enterprise Value	14.00B

Important Dates

The next estimated earnings date is Thursday, August 21, 2025.

Earnings Date	Aug 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Lepu Biopharma has 1.80 billion shares outstanding. The number of shares has increased by 1.87% in one year.

Current Share Class	1.75B
Shares Outstanding	1.80B
Shares Change (YoY)	+1.87%
Shares Change (QoQ)	+2.44%
Owned by Insiders (%)	33.45%
Owned by Institutions (%)	8.08%
Float	800.14M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	34.81
PB Ratio	18.78
P/TBV Ratio	42.69
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-31.98
EV / Sales	35.77
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-57.37

Financial Position

The company has a current ratio of 0.62, with a Debt / Equity ratio of 1.25.

Current Ratio	0.62
Quick Ratio	0.53
Debt / Equity	1.25
Debt / EBITDA	n/a
Debt / FCF	-3.71
Interest Coverage	-18.28

Financial Efficiency

Return on equity (ROE) is -54.02% and return on invested capital (ROIC) is -15.62%.

Return on Equity (ROE)	-54.02%
Return on Assets (ROA)	-10.61%
Return on Invested Capital (ROIC)	-15.62%
Return on Capital Employed (ROCE)	-32.00%
Revenue Per Employee	785,936
Profits Per Employee	-879,066
Employee Count	498
Asset Turnover	0.16
Inventory Turnover	2.87

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +158.56% in the last 52 weeks. The beta is -0.08, so Lepu Biopharma's price volatility has been lower than the market average.

Beta (5Y)	-0.08
52-Week Price Change	+158.56%
50-Day Moving Average	5.53
200-Day Moving Average	3.83
Relative Strength Index (RSI)	65.67
Average Volume (20 Days)	48,420,049

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Lepu Biopharma had revenue of HKD 391.40 million and -437.77 million in losses. Loss per share was -0.26.

Revenue	391.40M
Gross Profit	311.77M
Operating Income	-421.26M
Pretax Income	-451.41M
Net Income	-437.77M
EBITDA	-333.82M
EBIT	-421.26M
Loss Per Share	-0.26

Balance Sheet

The company has 506.54 million in cash and 904.72 million in debt, giving a net cash position of -398.18 million or -0.22 per share.

Cash & Cash Equivalents	506.54M
Total Debt	904.72M
Net Cash	-398.18M
Net Cash Per Share	-0.22
Equity (Book Value)	725.56M
Book Value Per Share	0.44
Working Capital	-423.55M

Cash Flow

In the last 12 months, operating cash flow was -209.00 million and capital expenditures -35.03 million, giving a free cash flow of -244.03 million.

Operating Cash Flow	-209.00M
Capital Expenditures	-35.03M
Free Cash Flow	-244.03M
FCF Per Share	-0.14

Margins

Gross margin is 79.66%, with operating and profit margins of -107.63% and -111.85%.

Gross Margin	79.66%
Operating Margin	-107.63%
Pretax Margin	-115.33%
Profit Margin	-111.85%
EBITDA Margin	-85.29%
EBIT Margin	-107.63%
FCF Margin	n/a

Dividends & Yields

Lepu Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.87%
Shareholder Yield	n/a
Earnings Yield	-3.21%
FCF Yield	-1.79%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Lepu Biopharma has an Altman Z-Score of -0.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.28
Piotroski F-Score	3